

What is claimed is:

1. An isolated nucleic acid comprising a transcriptional unit encoding a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus, wherein the transcriptional unit directs the synthesis of the antigen.
2. The nucleic acid of claim 1, wherein the signal sequence is a Japanese encephalitis virus signal sequence.
3. The nucleic acid of claim 1, wherein the immunogenic flavivirus antigen is of a flavivirus selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
4. The nucleic acid of claim 1, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus.
5. The nucleic acid of claim 1, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus and an M protein and an E protein of yellow fever virus.
6. The nucleic acid of claim 1, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus and an M protein and an E protein of St. Louis encephalitis virus.
7. The nucleic acid of claim 1, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus and an M protein and an E protein of Powassan virus.

8. The nucleic acid of claim 1, wherein the antigen is selected from the group consisting of an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and both a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus or any combination thereof.
9. The nucleic acid of claim 8, wherein the antigen is both the M protein and the E protein of a flavivirus.
10. The nucleic acid of claim 1, wherein the nucleic acid is DNA.
11. The nucleic acid of claim 10, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23.
12. The nucleic acid of claim 1, wherein the transcriptional unit comprises a control sequence disposed appropriately such that it operably controls the synthesis of the antigen.
13. The nucleic acid of claim 12, wherein the control sequence is the cytomegalovirus immediate early promoter.
14. The nucleic acid of claim 1, comprising a Kozak consensus sequence located at a translational start site for a polypeptide comprising the antigen encoded by the TU.
15. The nucleic acid of claim 1 wherein the transcriptional unit comprises a poly-A terminator.
16. A cell comprising the nucleic acid of claim 1.

17. A composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.
18. A method of immunizing a subject against infection by a flavivirus, comprising administering to the subject an effective amount of the composition of claim 17.
19. The method of claim 18, wherein the flavivirus antigen is of a flavivirus selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.
20. The method of claim 18, wherein the antigen is selected from the group consisting of an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and both a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus or any combination thereof.
21. The method of claim 20, wherein the antigen is both the M protein and the E protein of a flavivirus, and wherein a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M protein and the E protein.
22. The method of claim 18, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus, and an M protein and an E protein of West Nile virus.
23. The method of claim 18, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus, and an M protein and an E protein of yellow fever virus.

24. The method of claim 18, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus, and an M protein and an E protein of St. Louis encephalitis virus.

25. The method of claim 18, wherein the transcriptional unit encodes a signal sequence of Japanese encephalitis virus, and an M protein and an E protein of Powassan virus.

26. The method of claim 18, comprising administering the composition to the subject in a single dose.

27. The method of claim 18, wherein the composition is administered via a parenteral route.

28. The nucleic acid of claim 1, wherein the antigen is a St. Louis encephalitis virus antigen.

29. The method of claim 18, wherein the antigen is a St. Louis encephalitis virus antigen.

30. The nucleic acid of claim 1, wherein the antigen is a Japanese encephalitis virus antigen.

31. The method of claim 18, wherein the antigen is a Japanese encephalitis virus antigen.

32. The nucleic acid of claim 1, wherein the antigen is a yellow fever virus antigen.

33. The method of claim 18, wherein the antigen is a yellow fever virus antigen.

2013-04-24 10:51:30

34. The nucleic acid of claim 1, wherein the antigen is a dengue virus antigen.
35. The method of claim 18, wherein the antigen is a dengue virus antigen.
36. The nucleic acid of claim 1, wherein the antigen is a West Nile virus antigen.
37. The method of claim 18, wherein the antigen is a West Nile virus antigen.
38. An antigen produced from the nucleic acid of claim 1.
39. A method of detecting a flavivirus antibody in a sample, comprising:  
(a) contacting the sample with the antigen of claim 38 under conditions whereby an antigen/antibody complex can form; and  
(b) detecting antigen/antibody complex formation, thereby detecting a flavivirus antibody in the sample.
40. An antibody produced in response to immunization by the antigen of claim 38.
41. A method of detecting a flavivirus antigen in a sample, comprising:  
(a) contacting the sample with the antibody of claim 40 under conditions whereby an antigen/antibody complex can form; and  
(b) detecting antigen/antibody complex formation, thereby detecting a flavivirus antigen in a sample.
42. A method of diagnosing a flavivirus infection in a subject, comprising:  
(a) contacting a sample from the subject with the antigen of claim 38 under conditions whereby an antigen/antibody complex can form; and  
(b) detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.

43. A method of diagnosing a flavivirus infection in a subject, comprising:
- (a) contacting a sample from the subject with the antibody of claim 40 under conditions whereby an antigen/antibody complex can form; and
  - (b) detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.

098415-04404  
FOIb0-5762860